Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

NCT00519389 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Pandemic Influenza

Interventions

BIOLOGICAL: H5N1 VLP Vaccine
BIOLOGICAL: Placebo

Sponsor

Novavax